These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20604735)

  • 1. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity.
    Kam PC; Thompson JF
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1039-45. PubMed ID: 20604735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.
    Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS
    Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Melanoma Res; 2009 Apr; 19(2):106-11. PubMed ID: 19282789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution.
    Huismans AM; Kroon HM; Kam PC; Thompson JF
    Ann Surg Oncol; 2011 Jul; 18(7):1877-83. PubMed ID: 21499810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of an automated circuit for isolated limb infusion for malignancy.
    Grobmyer SR; Filichia L; Robinson AR; Clark TD; Vaughn K; Copeland EM; Hochwald SN
    Eur J Surg Oncol; 2010 Dec; 36(12):1215-9. PubMed ID: 20947288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion.
    Mian R; Henderson MA; Speakman D; Finkelde D; Ainslie J; McKenzie A
    Can J Surg; 2001 Jun; 44(3):189-92. PubMed ID: 11407828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
    Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
    J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
    Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
    Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
    Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
    Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US.
    Santillan AA; Zager JS
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1033-7. PubMed ID: 20078252
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
    Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
    Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
    Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.